Wang Lu, Zhao Jun, An Tongtong, Wang Yuyan, Zhuo Minglei, Wu Meina, Wang Ziping, Li Jianjie, Yang Xue, Chen Hanxiao, Zhong Jia
Department of Radiotherapy, Peking University Third Hospital, Beijing, China.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Medical Oncology-I, Peking University Cancer Hospital and Institute, Beijing, China.
Front Oncol. 2020 Jul 16;10:1137. doi: 10.3389/fonc.2020.01137. eCollection 2020.
Primary mediastinal germ cell tumors (PMGCTs) are rare. The natural history and optimal treatment strategies still need to be defined. The aim of the study was to summarize the clinical characteristics, treatment outcomes, and prognostic factors of PMGCTs. Twenty-four patients with PMGCTs who were treated from December 2008 to January 2019 were evaluated retrospectively. The Kaplan-Meier method and Cox regression analysis were used to evaluate factors associated with prognosis. The study population consisted of 23 male patients and 1 female patient. Five patients were diagnosed with seminoma and 19 patients were diagnosed with nonseminoma. The median follow-up time for all patients was 15.8 (3.9-114.5) months. The 5-year overall survival (OS) and progression free survival (PFS) rates for all patients were 65.2 and 44.3%. For nonseminoma and seminoma, the 5-year OS rates were 54.1 and 100% ( = 0.093), respectively, and the 5-year PFS rates were 28.7 and 100%, respectively ( = 0.044). In patients with nonseminoma, first-line radiotherapy indicated superior OS and PFS ( = 0.037 and 0.027, respectively). The median survival time after recurrence was 4.3 months and the 1-year survival rate after recurrence was 23.4%. These results indicated that in PMGCTs, the prognosis of seminoma is superior to that of nonseminoma. Radiotherapy may be an essential treatment in patients with nonseminoma. Patients with relapse have unfavorable prognosis.
原发性纵隔生殖细胞肿瘤(PMGCTs)较为罕见。其自然病史和最佳治疗策略仍有待明确。本研究的目的是总结PMGCTs的临床特征、治疗结果及预后因素。对2008年12月至2019年1月期间接受治疗的24例PMGCTs患者进行回顾性评估。采用Kaplan-Meier法和Cox回归分析评估与预后相关的因素。研究人群包括23例男性患者和1例女性患者。5例患者被诊断为精原细胞瘤,19例患者被诊断为非精原细胞瘤。所有患者的中位随访时间为15.8(3.9 - 114.5)个月。所有患者的5年总生存率(OS)和无进展生存率(PFS)分别为65.2%和44.3%。对于非精原细胞瘤和精原细胞瘤,5年OS率分别为54.1%和100%(P = 0.093),5年PFS率分别为28.7%和100%(P = 0.044)。在非精原细胞瘤患者中,一线放疗显示出更好的OS和PFS(分别为P = 0.037和0.027)。复发后的中位生存时间为4.3个月,复发后的1年生存率为23.4%。这些结果表明,在PMGCTs中,精原细胞瘤的预后优于非精原细胞瘤。放疗可能是非精原细胞瘤患者的重要治疗方法。复发患者预后不良。